IRF3 and breast cancer: Furthermore, we employed capivasertib, an AKT inhibitor that has been approved by FDA, to detect its effect on the cGAS‐STING pathway, and the results showed that capivasertib could significantly improve HT‐DNA‐induced phosphorylation of TBK1 and IRF3 in endocrine resistant breast cancer cells (R‐MCF7/R‐ZR75.1) (Figure S5B, Supporting Information).